Clinical Pharmacokinetics of the CD19 Receptor‐Directed Tyrosine Kinase Inhibitor B43‐Genistein in Patients with B‐Lineage Lymphoid Malignancies

@article{Chen1999ClinicalPO,
  title={Clinical Pharmacokinetics of the CD19 Receptor‐Directed Tyrosine Kinase Inhibitor B43‐Genistein in Patients with B‐Lineage Lymphoid Malignancies},
  author={Chun-Lin Chen and Alexandra M. Levine and Asha Rao and Karen O'Neill and Yoav H. Messinger and Dorothea E. Myers and Frederick D. Goldman and Carole Hurvitz and James T. Casper and Fatih M. Uckun},
  journal={The Journal of Clinical Pharmacology},
  year={1999},
  volume={39}
}
The authors examined the pharmacokinetics of the CD 19 receptor‐directed tyrosine kinase inhibitor B43‐Genistein in 17 patients (4 children, 13 adults) with B‐lineage lymphoid malignancies, including 12 patients with acute lymphoblastic leukemia (ALL) and 5patients with non‐Hodgkin's lymphoma (NHL). The immune conjugate was administered intravenously as a 1‐hour continuous infusion at a dose level of either 0.1 mg/kg (N = 12) or 0.18 mg/kg (N = 5), and the plasma concentration‐time data were… 
Bioavailability and Pharmacokinetic Features of Etoposide in Childhood Acute Lymphoblastic Leukemia Patients
TLDR
The bioavailability and pharmacokinetic characteristics of etoposide were studied in 12 relapsed B-lineage acute lymphoblastic leukemia patients after both intravenous (i.v.) infusion and oral administration and to the authors' knowledge, this is the first report concerning the bioavailability of etiposide in pediatric leukemia patients.
In vivo pharmacokinetics and metabolism of anti-human immunodeficiency virus agent D4T-5'-[p-bromophenyl methoxyalaninyl phosphate] (SAMPIDINE) in mice.
TLDR
It is reported that HI-113 forms two active metabolites with favorable pharmacokinetics after systemic administration and is converted to the active metabolites alaninyl-d4T-monophosphate (ala-d 4T-MP) and d4T.
ANTI-HUMAN IMMUNODEFICIENCY VIRUS AGENT D 4 T-5 *-[ P-BROMOPHENYL METHOXYALANINYL PHOSPHATE ] ( SAMPIDINE ) IN MICE
TLDR
It is reported that HI-113 forms two active metabolites with favorable pharmacokinetics after systemic administration and this promising new anti-HIV agent in mice exhibits substantially more potent anti-human immunodeficiency virus activity than d4T.
Recombinant human CD19‐ligand protein as a potent anti‐leukaemic agent
TLDR
CD19‐L is the first CD19‐specific recombinant human protein with potent anti‐leukaemic activity against B‐lineage acute lymphoblastic leukaemia (ALL) and other B‐ lineage lymphoid malignancies as well as B‐cell lymphoproliferative states and systemic autoimmunity.
Targeting of cytotoxic peptides to haematological malignancies
TLDR
The data here suggest that anti-CD 19 D(KLAKLAK)2 displays a highly selective and potent cytotoxic activity against CLL cells and may be of therapeutic value in the treatment of this incurable leukaemia.
Role of Clinical Pharmacokinetics Studies in Contemporary Oncology Drug Development
  • F. Uckun, S. Qazi
  • Medicine, Biology
    Drug Discovery and Evaluation: Methods in Clinical Pharmacology
  • 2018
Pharmacokinetics (PK) studies enable drug developers to elucidate the relationship of dose to blood concentrations of drugs in various patient populations and determining the need for dose adjustment
Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects
TLDR
Overall, it can be stated that MoAb therapy in ALL is a promising treatment approach, and higher effectivity can be expected from a combination with chemotherapy and treatment in the state of minimal residual disease.
Selective apoptotic killing of malignant hemopoietic cells by antibody-targeted delivery of an amphipathic peptide.
TLDR
It is suggested that amphipathic peptides may be of value as targeted therapeutic agents for the treatment of a subset of hematologic malignancies.
Tyrosine kinase inhibitors in cancer therapy.
In vivo antitumor activity of bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(IV) (METVAN [VO(SO4)(Me2-Phen)2]).
TLDR
The favorable in vivo pharmacodynamic features and antitumor activity of METVAN warrants further development of this novel oxovanadium compound as a potential new anticancer agent.
...
...

References

SHOWING 1-10 OF 22 REFERENCES
In vivo toxicity and pharmacokinetic features of B43(Anti-CD19)-Genistein immunoconjugate.
B43(anti-CD19)-Genistein immunoconjugate targets genistein, a naturally occurring protein tyrosine kinase inhibitory isoflavone to the membrane-associated anti-apoptotic CD19-LYN complexes and
Pharmacokinetic features, immunogenicity, and toxicity of B43(anti-CD19)-pokeweed antiviral protein immunotoxin in cynomolgus monkeys.
  • F. Uckun, Y. Yanishevski, R. Gunther
  • Medicine, Biology
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1997
TLDR
The present study completes the preclinical evaluation of B43-PAP and provides the basis for its clinical evaluation in children with therapy-refractory B-lineage acute lymphoblastic leukemia.
Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases
TLDR
The B43-Gen immunoconjugate bound with high affinity to BCP leukemia cells, selectively inhibited CD19-associated tyrosine kinases, and triggered rapid apoptotic cell death, which led to 100 percent long-term event-free survival from an otherwise invariably fatal leukemia.
In vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factor.
  • F. Uckun, R. Narla, W. Evans
  • Biology, Medicine
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1998
TLDR
EGF-Gen significantly improved tumor-free survival in a severe combined immune deficiency mouse xenograft model of human breast cancer, when it was administered 24 h after inoculation of tumor cells, and was more effective than cyclophosphamide, Adriamycin, or methotrexate, the most widely used standard chemotherapeutic drugs for breast cancer.
Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition.
  • D. Ferry, A. Smith, D. Kerr
  • Medicine, Biology
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1996
TLDR
In conclusion, quercetin can be safely administered by i.v. bolus at a dose injection and evidence of antitumor activity was seen.
In vivo toxicity and pharmacokinetic features of B43 (anti-CD19)-genistein immunoconjugate in nonhuman primates.
TLDR
This is the first preclinical toxicity and pharmacokinetic study of a tyrosine kinase inhibitor-containing immunoconjugate in nonhuman primates and B43-genistein showed a favorable pharmacokinetics in monkeys.
In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022.
TLDR
The rapid in vivo elimination of RG13022 has potential significance to the development of this and other related tyrphostin tyrosine kinase inhibitors, as plasma concentrations fell below that required for in vitro activity by 20 min post injection.
Large scale manufacturing of B43(anti-CD19)-genistein for clinical trials in leukemia and lymphoma.
TLDR
To the knowledge, this work represents the first effort of producing a clinical-grade genistein immunoconjugate for treatment of B-lineage leukemia and lymphoma.
Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing pokeweed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic leukemia
TLDR
It is shown that B43- PAP can effectively eradicate leukemic progenitor cells freshly obtained from patients with common B-lineage ALL, and that these cells are sensitive to PAP at the ribosomal level.
Cellular Expression of Antiapoptotic BCL-2 Oncoprotein in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia: A Children's Cancer Group Study
TLDR
High BCL-2 levels in primary leukemic cells predicted slow early response only in T-lineage ALL patients, which comprised approximately 15% of the total patient population, and even for this small subset of patients, the level of Bcl-2 expression did not have a significant impact on the short-term event-free survival.
...
...